EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Role of antireflux mucosal ablation in “reflux-predominant” refractory gastroesophageal reflux disease: a randomized sham-controlled trial

Digvijay Chavan, Krithi Krishna Koduri iD, Aniruddha Pratap Singh, Rajesh Goud Maragoni, Nitin Jagtap iD, Rakesh Kalapala, D Nageshwar Reddy

Endoscopy · 01.05.2026 · 58 (05) · 456-464

DOI: 10.1055/a-2740-9297 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Endoscopy, erschienen am 01.05.2026. Verfasst von Digvijay Chavan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India. Hauptthemen laut MEDLINE: Endoscopic Mucosal Resection, Gastroesophageal Reflux. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Refractory gastroesophageal reflux disease (GERD) often requires endoscopic or surgical intervention. We evaluated the efficacy of antireflux mucosal ablation (ARMA) versus sham treatment in patients with reflux-predominant refractory GERD. This single-center, randomized sham-controlled trial enrolled patients with persistent GERD symptoms on optimized proton pump inhibitor (PPI) therapy, with acid exposure time (AET) 80 reflux episodes on 24-hour pH-impedance monitoring. Patients were randomized to the ARMA or sham groups. The primary outcome was the proportion of patients achieving 50% improvement in GERD health-related quality-of-life (GERD-HRQL) score from baseline to 6 months. Secondary outcomes included heartburn and regurgitation symptom scores, AET, DeMeester score, reflux episodes, endoscopy findings, and PPI consumption. Mixed-effects models were applied, with group (ARMA vs. sham) as fixed effect and participant as random effect. 58 patients (ARMA, n = 28; median age 41; 32% women vs. sham, n = 30; median age 40; 36% women) were included. Baseline mean (SD) duration of PPI use was similar: ARMA, 3.5 (2.7) years; sham, 3.7 (1.8) years. At 6 months, 20 of the ARMA group (71.4%) achieved ≥50% GERD-HRQL score reduction vs. one in the sham group (3.6%; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endoscopic Mucosal ResectionGastroesophageal RefluxAdultFemaleHumansMaleMiddle AgedEsophageal pH MonitoringHeartburnProton Pump InhibitorsQuality of LifeTreatment Outcome

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.

ORCID-Profile: Krithi Krishna Koduri, Nitin Jagtap

Zitieren

APA

Chavan, D., Koduri, K. K., Singh, A. P., Maragoni, R. G., Jagtap, N., Kalapala, R., & Reddy, D. N. (2026). Role of antireflux mucosal ablation in “reflux-predominant” refractory gastroesophageal reflux disease: a randomized sham-controlled trial. Endoscopy, 58(05), 456-464. https://doi.org/10.1055/a-2740-9297

Vancouver

Chavan D, Koduri KK, Singh AP, Maragoni RG, Jagtap N, Kalapala R, et al. Role of antireflux mucosal ablation in “reflux-predominant” refractory gastroesophageal reflux disease: a randomized sham-controlled trial. Endoscopy. 2026;58(05):456-464. doi:10.1055/a-2740-9297

BibTeX
@article{Chavan2026,
  author = {Chavan, Digvijay and Koduri, Krithi Krishna and Singh, Aniruddha Pratap and Maragoni, Rajesh Goud and Jagtap, Nitin and Kalapala, Rakesh and Reddy, D Nageshwar},
  title = {Role of antireflux mucosal ablation in “reflux-predominant” refractory gastroesophageal reflux disease: a randomized sham-controlled trial},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {05},
  pages = {456--464},
  doi = {10.1055/a-2740-9297}
}
Kostenlos starten →